Biohaven [BHVN] vs Cg Oncology [CGON] Detailed Stock Comparison
Biohaven
NYSE
Loading...
Cg Oncology
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Biohaven wins in 1 metrics, Cg Oncology wins in 12 metrics, with 1 ties. Cg Oncology appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biohaven | Cg Oncology | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.64 | -18.13 | Cg Oncology |
| Price-to-Book Ratio | 12.35 | 2.97 | Cg Oncology |
| Debt-to-Equity Ratio | 25.63 | 0.15 | Cg Oncology |
| PEG Ratio | 0.04 | -0.20 | Cg Oncology |
| EV/EBITDA | -1.39 | -8.48 | Cg Oncology |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 0.00% | -28,546.10% | Biohaven |
| Return on Equity | -295.94% | -12.00% | Cg Oncology |
| Return on Assets (TTM) | -103.41% | -11.66% | Cg Oncology |
| Free Cash Flow (TTM) | $-586.50M | $-78.95M | Cg Oncology |
| 1-Year Return | -64.82% | -29.82% | Cg Oncology |
| Price-to-Sales Ratio (TTM) | N/A | 3,615.88 | N/A |
| Enterprise Value | $1.29B | $1.33B | Cg Oncology |
| EV/Revenue Ratio | N/A | 2,417.95 | N/A |
| Revenue per Share (TTM) | $0 | $0 | Cg Oncology |
| Earnings per Share (Diluted) | $-7.46 | $-1.81 | Cg Oncology |
| Beta (Stock Volatility) | 3.50 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biohaven vs Cg Oncology Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biohaven | -0.14% | 3.16% | 6.30% | -6.50% | -60.23% | -60.62% |
| Cg Oncology | 1.76% | 0.08% | -3.42% | -0.92% | -6.71% | -10.32% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biohaven | -64.82% | 101.10% | 101.10% | -18.03% | -18.03% | -18.03% |
| Cg Oncology | -29.82% | -25.83% | -25.83% | -25.83% | -25.83% | -25.83% |
Performance & Financial Health Analysis: Biohaven vs Cg Oncology
| Metric | BHVN | CGON |
|---|---|---|
| Market Information | ||
| Market Cap | $1.66B | $1.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,885,210 | 673,830 |
| 90 Day Avg. Volume | 1,925,720 | 903,963 |
| Last Close | $14.68 | $25.98 |
| 52 Week Range | $12.79 - $55.70 | $14.80 - $40.47 |
| % from 52W High | -73.64% | -35.80% |
| All-Time High | $67.86 (Jun 03, 2019) | $50.23 (Feb 12, 2024) |
| % from All-Time High | -78.37% | -48.28% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -1.00% |
| Quarterly Earnings Growth | N/A | -1.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | -285.46% |
| Return on Equity (TTM) | -2.96% | -0.12% |
| Debt to Equity (MRQ) | 25.63 | 0.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.27 | $8.79 |
| Cash per Share (MRQ) | $3.83 | $8.67 |
| Operating Cash Flow (TTM) | $-645,078,016 | $-93,817,000 |
| Levered Free Cash Flow (TTM) | $-508,353,632 | $396.48M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Biohaven vs Cg Oncology
| Metric | BHVN | CGON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.64 | -18.13 |
| Forward P/E | -2.49 | -14.68 |
| PEG Ratio | 0.04 | -0.20 |
| Price to Sales (TTM) | N/A | 3,615.88 |
| Price to Book (MRQ) | 12.35 | 2.97 |
| Market Capitalization | ||
| Market Capitalization | $1.66B | $1.99B |
| Enterprise Value | $1.29B | $1.33B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 2,417.95 |
| Enterprise to EBITDA | -1.39 | -8.48 |
| Risk & Other Metrics | ||
| Beta | 3.50 | N/A |
| Book Value per Share (MRQ) | $1.27 | $8.79 |
Financial Statements Comparison: Biohaven vs Cg Oncology
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BHVN | CGON |
|---|---|---|
| Revenue/Sales | $0 | $52,000 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | $187.58M | $27.47M |
| Operating Income (EBIT) | $-221.56M | $-42.20M |
| EBITDA | $-219.32M | $-42.18M |
| Pre-Tax Income | $-221.07M | $-34.45M |
| Income Tax | $609,000 | N/A |
| Net Income (Profit) | $-221.68M | $-34.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BHVN | CGON |
|---|---|---|
| Cash & Equivalents | $98.42M | $41.47M |
| Total Current Assets | $382.76M | $701.19M |
| Total Current Liabilities | $164.03M | $22.64M |
| Long-Term Debt | $30.80M | $781,000 |
| Total Shareholders Equity | $259.50M | $704.76M |
| Retained Earnings | $-1.57B | $-252.43M |
| Property, Plant & Equipment | $36.78M | $1.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BHVN | CGON |
|---|---|---|
| Operating Cash Flow | $-164.28M | $-28.85M |
| Capital Expenditures | $-461,000 | $-16,000 |
| Free Cash Flow | $-165.59M | $-29.29M |
| Debt Repayment | N/A | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BHVN | CGON |
|---|---|---|
| Shares Short | 12.71M | 11.00M |
| Short Ratio | 6.72 | 11.27 |
| Short % of Float | 0.14% | 0.15% |
| Average Daily Volume (10 Day) | 1,885,210 | 673,830 |
| Average Daily Volume (90 Day) | 1,925,720 | 903,963 |
| Shares Outstanding | 101.22M | 76.15M |
| Float Shares | 88.38M | 61.28M |
| % Held by Insiders | 0.12% | 0.01% |
| % Held by Institutions | 0.83% | 1.12% |
Dividend Analysis & Yield Comparison: Biohaven vs Cg Oncology
| Metric | BHVN | CGON |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |